11/15/2019 7:33:20 AM
Rigel Receives Positive CHMP Opinion For Fostamatinib Disodium Hexahydrate In Europe
11/5/2019 4:05:49 PM
Rigel Q3 Loss/share $0.07 Vs. Loss $0.14 Year Ago
10/23/2019 7:36:23 AM
Rigel Provides Business Update
10/18/2019 7:35:30 AM
Rigel Gets Positive Trend Vote From CHMP For Fostamatinib For Chronic Immune Thrombocytopenia In Europe
10/2/2019 7:01:58 AM
Rigel Pharma Enters $60 Mln Term Loan Credit Facility With MidCap Financial
9/23/2019 7:32:06 AM
Rigel's Fostamatinib Enters Phase 3 Clinical Trial In Japan With Kissei For Treatment Of Chronic Immune Thrombocytopenia
8/6/2019 4:10:02 PM
Rigel Pharma Q2 Loss/share $0.12 Vs. Loss $0.16 Year Ago
6/13/2019 7:32:48 AM
Rigel Pharma To Present Data On Fostamatinib In Two Posters At 24th Congress Of EHA
5/16/2019 7:32:26 AM
Rigel Enrolls First Patient In Phase 3 Trial Of Fostamatinib Disodium Hexahydrate In Warm Autoimmune Hemolytic Anemia
5/7/2019 4:05:08 PM
Rigel Pharma Q1 Loss/share $0.11 Vs. Loss $0.17 Year Ago
3/26/2019 7:31:21 AM
Rigel Welcomes Jane Wasman To Board